Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06975293 · ClinicalTrials.gov registry record · Phase 1
STC-15 as a Part of Combination Therapy With Toripalimab in Selected Advanced Cancers
A Phase 1 study of Solid Tumor and Metastatic Melanoma, sponsored by STORM Therapeutics.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 188
- Enrollment target
- 3
- Study locations
NCT06975293 is a Phase 1 study of Solid Tumor and Metastatic Melanoma that is actively recruiting participants, run by STORM Therapeutics. The registered enrollment target is 188 participants, below the 221-participant average among 196 other Solid Tumor trials with a reported enrollment target (15% lower). The trial reports 3 study locations across 3 states.
The verdict
NCT06975293, a Phase 1 study of Solid Tumor and Metastatic Melanoma, is actively recruiting participants, sponsored by STORM Therapeutics.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 188 participants
- Enrollment target
- 3
- Study locations
Study Summary
This early phase oncology trial will be conducted at various study centers to investigate the safety, tolerability, and antitumor activity of STC-15 (a METTL3 inhibitor) in combination with toripalimab (anti- programmed cell death 1 \[PD-1\]) in four different locally advanced unresectable or metastatic tumors such as indications: (1) in combination with toripalimab (anti- programmed cell death 1 \[PD-1\]) in locally advanced and unresectable or metastatic non-small cell lung cancer (NSCLC), (2) in combination with toripalimab in locally advanced unresectable or metastatic melanoma, (3) in combination with toripalimab in locally advanced unresectable or metastatic endometrial cancers, and (4) in combination with toripalimab in locally advanced or metastatic head and neck squamous cell carcinoma (HNSCC). This study comprises of 2 parts: a combination dose escalation part (Phase 1b) followed by an assessment of the combination treatment's antitumor activity (Phase 2). This study will be conducted in adult participants with advanced malignancies to characterize the safety, tolerability, PK, and clinical activity of STC-15 in combination with toripalimab.
Conditions Studied
Interventions
- COMBINATION_PRODUCT STC-15 in combination with toripalimab
Study Locations (3)
New York
- Northwell Health Cancer Institute - Lake Success
Texas
- The START Center - San Antonio
Virginia
- NEXT Oncology - Fairfax
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 188 participants |
| Start Date | 2025-05-05 |
| Est. Completion | 2027-06-29 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06975293
The ClinicalTrials.gov registry entry for NCT06975293 describes a study currently listed as recruiting, categorized as Phase 1. The registered enrollment target is 188 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 221-participant average among 196 other Solid Tumor trials with a reported enrollment target (15% lower). The listed sponsor is STORM Therapeutics, which has 2 total studies on file at ClinicalTrials.gov.
The record links to 5 conditions, with Solid Tumor appearing as the primary indexed condition, and to 1 intervention - of which STC-15 in combination with toripalimab is the first listed.
NCT06975293 reports 3 study locations spanning 3 distinct geographic areas - top geographies include New York, Texas, Virginia.
Frequently Asked Questions
What is clinical trial NCT06975293 about?
NCT06975293 is a clinical study titled "STC-15 as a Part of Combination Therapy With Toripalimab in Selected Advanced Cancers". This early phase oncology trial will be conducted at various study centers to investigate the safety, tolerability, and antitumor activity of STC-15 (a METTL3 inhibitor) in combination with toripalimab (anti- programmed cell death 1 \[PD-1\]) in four different locally advanced unresectable or metast...
What is the current status of trial NCT06975293?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 188 participants. The study started on 2025-05-05. Estimated completion is 2027-06-29.
What conditions does trial NCT06975293 study?
This clinical trial studies the following conditions: Solid Tumor, Metastatic Melanoma, Metastatic Non Small Cell Lung Cancer, Metastatic Head-and-neck Squamous-cell Carcinoma, Metastatic Endometrial Cancer.
What interventions are being tested in trial NCT06975293?
The interventions under investigation include: STC-15 in combination with toripalimab (COMBINATION_PRODUCT).
Who is sponsoring clinical trial NCT06975293?
This trial is sponsored by STORM Therapeutics, which has 2 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06975293 being conducted?
This trial has 3 study locations across New York, Texas, Virginia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Solid Tumor
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Study to Evaluate Safety, Efficacy, and Pharmacokinetics in Participants With Advanced Solid Tumors
RECRUITING · Phase 1
-
A Phase I Study of ROSE12 Alone and in Combination With Other Anti-tumor Agents in Patients With Solid Tumors
RECRUITING · Phase 1
-
Phase I Study of Tolododekin Alfa (ANK-101) in Advanced Solid Tumors
RECRUITING · Phase 1
-
Concurrent Azeliragon With Craniospinal Irradiation
RECRUITING · Phase 1
-
Safety and Tolerability of TNG456 Alone and in Combination With Abemaciclib in Patients With Solid Tumors With MTAP Loss
RECRUITING · Phase 1
-
A Study Investigating BGB-26808 Alone or in Combination With Tislelizumab in Participants With Advanced Solid Tumors
RECRUITING · Phase 1
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.